Jonathan S Berek1, Candace Howe, Leo D Lagasse, Neville F Hacker. 1. Division of Gynecologic Oncology, David Geffen School of Medicine, University of California-Los Angeles, UCLA Center for the Health Sciences 24-127, 10833 LeConte Avenue, Los Angeles, CA 90095-1740, USA. jberek@mednet.ucla.edu
Abstract
OBJECTIVE: To retrospectively assess the outcome of patients undergoing pelvic exenteration for recurrent or persistence gynecologic malignancy and the clinical features associated with outcome and survival. METHODS: A review was conducted of patients who underwent pelvic exenteration over a 45-year period (1956-2001) at the UCLA Medical Center. Numerous clinical variables were analyzed, including time to relapse, type of exenteration and reconstructive operation, early (<60 days) and late (>60 days) morbidity, and survival. Variables were analyzed by chi-square and life-table analysis. RESULTS: Seventy-five patients (ages 26-74 years) had persistent cervical and vaginal (67) and uterine (8) cancer. Forty-six patients underwent total exenteration, 23 anterior, and 6 posterior. Sixty-nine (92%) patients underwent urinary diversion or neocystoplasty, 54 (72%) patients had a simultaneous neovagina created, and 43 of 52 (83%) patients who had a low colon resection had a primary reanastomosis. Twenty-nine patients died from recurrent malignancy, 28 were alive without disease, 11 were alive with disease, and 7 died from other causes at last follow-up. Survival for patients with cervical and vaginal cancer was 73% at 1 year, 57% at 3 years, and 54% at 5 years. Survival for patients with uterine cancer was 86% at 1 year, 62% at 3 and 5 years. The most frequent early morbidity was urinary tract infection, wound infection, and intestinal fistula; the most frequent late morbidity was urinary tract infection and intestinal obstruction. CONCLUSION: Pelvic exenteration in patients with recurrent cervical and vaginal malignancy is associated with a durable > 50% 5-year survival. Simultaneously performed pelvic reconstructive operations with a continent urinary diversion, the creation of a neovagina, and the reanastomosis of the colon with the formation of a J-pouch is now our standard; and these operations tend to improve the outcome of patients. Based on our initial experience, recurrent uterine corpus cancer in young women (< 55 years) should be included as an indication for the surgery.
OBJECTIVE: To retrospectively assess the outcome of patients undergoing pelvic exenteration for recurrent or persistence gynecologic malignancy and the clinical features associated with outcome and survival. METHODS: A review was conducted of patients who underwent pelvic exenteration over a 45-year period (1956-2001) at the UCLA Medical Center. Numerous clinical variables were analyzed, including time to relapse, type of exenteration and reconstructive operation, early (<60 days) and late (>60 days) morbidity, and survival. Variables were analyzed by chi-square and life-table analysis. RESULTS: Seventy-five patients (ages 26-74 years) had persistent cervical and vaginal (67) and uterine (8) cancer. Forty-six patients underwent total exenteration, 23 anterior, and 6 posterior. Sixty-nine (92%) patients underwent urinary diversion or neocystoplasty, 54 (72%) patients had a simultaneous neovagina created, and 43 of 52 (83%) patients who had a low colon resection had a primary reanastomosis. Twenty-nine patients died from recurrent malignancy, 28 were alive without disease, 11 were alive with disease, and 7 died from other causes at last follow-up. Survival for patients with cervical and vaginal cancer was 73% at 1 year, 57% at 3 years, and 54% at 5 years. Survival for patients with uterine cancer was 86% at 1 year, 62% at 3 and 5 years. The most frequent early morbidity was urinary tract infection, wound infection, and intestinal fistula; the most frequent late morbidity was urinary tract infection and intestinal obstruction. CONCLUSION: Pelvic exenteration in patients with recurrent cervical and vaginal malignancy is associated with a durable > 50% 5-year survival. Simultaneously performed pelvic reconstructive operations with a continent urinary diversion, the creation of a neovagina, and the reanastomosis of the colon with the formation of a J-pouch is now our standard; and these operations tend to improve the outcome of patients. Based on our initial experience, recurrent uterine corpus cancer in young women (< 55 years) should be included as an indication for the surgery.
Authors: Jessica L Berger; Shannon N Westin; Bryan Fellman; Vijayashri Rallapali; Michael Frumovitz; Pedro T Ramirez; Anil K Sood; Pamela T Soliman Journal: Gynecol Oncol Date: 2011-12-11 Impact factor: 5.482
Authors: Paul J Speicher; Ryan S Turley; Jason L Sloane; Christopher R Mantyh; John Migaly Journal: J Gastrointest Surg Date: 2013-11-08 Impact factor: 3.452
Authors: Olivio F Donati; Yulia Lakhman; Evis Sala; Irene A Burger; Hebert A Vargas; Debra A Goldman; Vaagn Andikyan; Kay J Park; Dennis S Chi; Hedvig Hricak Journal: Eur Radiol Date: 2013-05-08 Impact factor: 5.315
Authors: Yulia Lakhman; Stephanie Nougaret; Maura Miccò; Chiara Scelzo; Hebert A Vargas; Ramon E Sosa; Elizabeth J Sutton; Dennis S Chi; Hedvig Hricak; Evis Sala Journal: Radiographics Date: 2015 Jul-Aug Impact factor: 5.333
Authors: David A Iglesias; Shannon N Westin; Vijayashri Rallapalli; Marilyn Huang; Bryan Fellman; Diana Urbauer; Michael Frumovitz; Pedro T Ramirez; Pamela T Soliman Journal: Gynecol Oncol Date: 2012-01-16 Impact factor: 5.482
Authors: F T J Ferenschild; M Vermaas; C Verhoef; A C Ansink; W J Kirkels; A M M Eggermont; J H W de Wilt Journal: World J Surg Date: 2009-07 Impact factor: 3.352